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1	–	Introduction	
Renal	Cell	Carcinoma		Renal	cell	carcinoma	(RCC)	is	a	heterogeneous	disease	accounting	for	about	90%	of	all	renal	malignancies	and	1%	to	3%	of	all	malignant	visceral	neoplasms.	Over	 the	past	 few	decades	there	 has	 been	 a	 significant	 rise	 in	 incidence,	 likely	 explained	with	 the	 recent	 advances	 in	imaging	 technology	 in	 the	 diagnosis	 of	 localized	 cancer	 and	 the	 increase	 use	 of	 imaging	 in	medical	practice	[1,2].		RCC	includes	multiple	subtypes	that	differ	in	their	histopathologic	features,	genetic	expression	pattern,	and	clinical	behaviour.	During	 the	 last	 2	 decades,	 significant	 advances	 in	 the	 diagnosis,	 staging,	 and	 treatment	 of	patients	with	RCC	have	resulted	in	improved	survival	in	selected	patients	[3].		Recent	discoveries	in	the	genetics	of	RCC	have	provided	the	opportunity	for	new	molecularly	targeted	 therapies	 in	 patients	 with	 metastatic	 RCC,	 including	 immunotherapy	 and	antiangiogenic	 therapies	 [4,5]	 The	 success	 of	 such	 targeted	 therapies	 relies	 on	 an	 accurate	histologic	subtyping	of	 the	 tumours.	Percutaneous	biopsy	can	provide	a	pre-surgical	 ‘‘tissue	diagnosis’’	in	selected	patients,	although	inaccurate	tumour	subtyping	rates	can	be	as	high	as	26%	in	sampled	primary	renal	tumours	[6,7].	Therefore,	a	method	to	accurately	characterize	the	histology	subtype	of	renal	masses	that	is	robust,	non-invasive,	and	insensitive	to	sampling	errors	would	have	utility	in	clinical	practice.	Approximately	 40%	 of	 patients	with	 RCC	 die	 because	 of	 the	 disease	 progression,	 thus	 this	tumour	is	the	most	lethal	malignant	urological	tumour.		Currently,	most	RCCs	are	incidentally	found	at	imaging	investigations.		
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Here	 is	 shown	 Table	 1	 with	 classification	 of	 Renal	 tumour	 as	 assessed	 by	 WHO	 2016	Classification	[8].		
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Clear	cell	renal	cell	carcinoma	is	the	most	common	variant,	representing	almost	75%	of	all	RCCs	[9,10].	 Only	 5%	 of	 ccRCC	 are	 associated	 with	 hereditary	 syndromes	 (von	 Hippel-Lindau	disease,	tuberous	sclerosis),	most	of	them	(95%)	are	sporadic.		Clear	cell	RCC	originates	from	the	proximal	convoluted	tubules	epithelium	(renal	cortex)	and	presents	a	predominantly	expansile	 growth	pattern.	Macroscopically,	 it	 is	 a	 solid,	 yellowish	lesion	with	variable	degrees	of	internal	necrosis,	hemorrhage	and	cystic	degeneration.	These	findings	 are	 most	 frequently	 observed	 in	 large-volume,	 fast-growing	 tumours.	 Tumour	calcifications	may	also	be	found.	Clear	cells	are	so	named	because	of	their	lipid-	and	glycogen-	rich	 cytoplasmic	 content	 [11].	 Frequently,	 these	 tumours	 also	 present	 cell	 with	 eosinophil	granular	cytoplasm.		Imaging	findings	reproduce	such	histopatological	features:	they	present	as	hypervascularized	and	heterogeneous	 lesions	due	 to	necrosis,	hemorrhage,	cysts	and	calcifications.	Necrosis	 is	more	common	generally	in	>	4	cm	lesions.	The	rate	of	occurrence	and	degree	of	necrosis	have	also	been	associated	with	high-grade	tumour	histology	[12,13].	At	computed	tomography	(CT),	ccRCC	usually	present	with	intense	contrast	enhancement	in	the	corticomedullary	phase	(120–140	HU)	and	typical	washout	in	the	nephrographic	phase	(90–100	HU).	At	MRI,	at	T1-weighted	images	we	can	find	signal	intensity	similar	to	the	one	of	the	renal	cortex,	and	 hypersignal	 at	 T2-weighted	 images.	 Up	 to	 60%	 of	 ccRCC	 because	 of	 the	 presence	 of	intracellular	lipid	content,	presents	signal	loss	at	out-of-phase	image	when	the	chemical	shift	imaging	technique	is	employed	[14].	It	should	be	observed	that	this	is	a	nonspecific	finding	of	ccRCC,	since	it	may	also	be	seen	in	angiomyolipoma	without	macroscopic	fat	and,	more	rarely,	also	 in	 pRCC.	 ccRCC	may	 also	 present	 a	 hypodense	 pseudocapsule	 in	 the	 corticomedullary	phase	at	CT,	and	with	hyposignal	at	MRI	T1-	and	T2-weighted	sequences.	Discontinuity	 of	 this	 pseudocapsule	 generally	 indicates	 a	 high-grade	 tumour.	 Quantitative	analysis	 of	 the	 contrast	 uptake	 by	 tumours	 at	multiphase	 examinations	 (cortico-medullary,	
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nephrographic	and	excretory	phases)	demonstrated	that	the	percentages	of	signal	alteration	in	the	three	phases	after	contrast	injection	in	relation	to	the	pre-contrast	phase	were	significantly	higher	in	ccRCC	than	in	pRCC	or	in	crRCC.	
Treatment	There	 is	a	wide	spectrum	of	drugs	with	a	good	activity	 in	advanced	or	metastatic	 renal	cell	carcinoma	[15].	There	is	agreement	on	recommending	targeted	agents	as	the	standard	of	care	in	this	disease.	Physicians	and	patients	may	select	sunitinib,	bevacizumab	in	combination	with	interferon-	alpha	(IFN-α),	pazopanib,	or—in	poor	risk	patients—temsirolimus.	There	are	also	a	 variety	 of	 therapies	 with	 proven	 efficacy	 on	 hand	 in	 the	 second-line	 setting:	 sorafenib,	pazopanib,	axitinib,	and	everolimus.		Currently,	seven	drug	or	drug	combinations	are	licensed	for	the	treatment	of	metastatic	RCC.	Crucial	for	this	progress	was	the	understanding	of	the	role	of	angiogenesis	in	general	and	the	VEGF-	and	mTOR-pathways	[16].	The	biggest	problem	in	RCC	is	relapse,	that’s	why	good	guidelines	for	the	correct	sequence	of	agents	is	needed	to	achieve	the	best	response,	at	least	stabilizing	the	disease.	The	sequence	for	using	these	therapies	is	an	ongoing	matter	of	debate	and	several	reviews	have	been	published	on	this	topic	over	the	past	years	[17]										
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Here	are	shown	tables	from	Fisher	et	All	[18]	which	show	treatment	option	at	first,	second	and	third	line.	
	
	 	
	Mechanisms	 of	 resistance	 to	 anti-angiogenetic	 therapy	 are	 multiple,	 one	 of	 these	 is	 up-regulation	of	alternative	pro-angiogenic	pathways	[19].	Further	studies	showed	up-regulation	of	 pro-angiogenic	 factors	 such	 as	 PDGF	 and	 FGF	 [20]	 after	 angiogenesis	 inhibition.	 Other	mechanism	 could	 be	 activation	 of	 mTOR-pathway	 which	 integrates	 information	 about	nutrients	and	growth	factors	and	has	a	central	role	in	cell	growth	and	cell	cycle	progression.	
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Microenviroment	 such	 as	 lower	 oxygen	 levels	 seem	 to	 lead	 to	 recruitment	 of	 vascular	progenitor	 cells	 from	 the	 bone	 marrow,	 while	 also	 pericytes	 or	 changes	 in	 more	 invasive	phenotype	(such	as	sarcoma-like	phenotype)	of	tumour	cells	has	been	studied	[21,22,23,24].	Moreover,	 in	the	recent	years,	 immunotherapeutic	agents	have	started	to	have	space	in	RCC	[25]	and	require	integration	in	treatment	algorithms	and	rethinking	of	the	treatment	sequence.		Immune	checkpoint	inhibitors	activate	the	immune	system	against	cancer	cells;	their	response	pattern	may	mimic	 tumour	 progression,	 and	 their	 class-specific	 toxicities	 (immune-related	adverse	events)	include	colitis,	pneumonitis,	and	sarcoid-like	reaction.												 	
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Radiogenomics	
 Deep	research	in	cancer	genomics	have	spread	more	and	more	interest	in	using	the	imaging	aspects	of	tumors	as	a	noninvasive	surrogate	marker	of	molecular	markers,	genomic	mutations	underlying	 activated	 biologic	 pathways,	 or	 clinical	 outcomes	 finding	 “association	 maps”	between	them,	to	complement	genomic	analysis.	This	is	called	radiogenomics	or	radiomics	or	imaging	genomics	[26].		The	current	literature	on	RCC	radiogenomics	has	focused	on	ccRCC.	Deactivating	mutation	of	the	VHL	tumour	suppressor	gene,	mutations	involving	the	BRCA1-associated	protein	1	(BAP1),	polybromo	1	(PBRM1),	SET	domain	containing	2	(SETD2),	and	lysine	(K)-	specific	demethylase	5C	(KDM5C)	have	been	identified	[27].	Clinical	relevance	of	these	mutation	is	significant:	VHL,	PBRM1,	BAP1,	SETD2,	and	KD-	M5C	mutations	are	shown	to	be	associated	with	advanced	stage	disease	and	poor	 survival.	 If	we	are	able	 to	 reliably	associate	 imaging	 features	of	RCC	with	mutational	 status,	 imaging	 could	 play	 a	 role	 in	 prognostication,	 treatment	 selection,	 and	predicting	 treatment	 response	Mutations	of	VHL	were	associated	with	well-defined	 tumour	margins,	 nodular	 tumour	 enhancement,	 and	 intratumoral	 vascularity,	 while	 mutations	 of	KDM5C	and	BAP1	were	associated	with	renal	vein	invasion	[28].	Mutations	of	VHL	and	PBRM1	were	also	more	common	among	solid	ccRCC	in	this	study.	BAP1	mutation	has	been	associated	with	ill-defined	tumour	margin	and	presence	of	calcification,	and	MUC4	mutation	is	associated	with	an	exophytic	growth	pattern	 [27].	A	 radiogenomic-based	surrogate	of	molecular	assay	(SOMA)	 for	 multigene	 signature	 of	 ccRCC	 has	 been	 built,	 using	 CT	 image	 features	 to	noninvasively	 predict	 the	 disease-specific	 survival	 independent	 from	 stage,	 grade,	 and	performance	 status	 [29].	 These	 efforts	 represent	 interesting	 starting	 steps	 in	 correlating	imaging	with	genetic	make-up	of	RCC.	Thera	are	some	limitation	nowadays	to	the	use	of	radiogenomics,	 the	biggest	at	present	are	
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limited	interobserver	agreement	in	multi-institutional	settings,	and	uncertain	generalizability	of	available	data	[27]	Morover,	validated	data	are	still	needed.		Growing	 interest	 in	 tumour	 texture	 analysis	 give	 a	 chance	 to	 investigators	 to	 predict	 gene	expression	 with	 the	 help	 of	 new	 tools.	 Tumour	 heterogeneity	 is	 a	 quantifiable	 feature	 on	images,	much	 like	 tumour	 size	or	attenuation.	Tumour	heterogeneity	 can	be	quantified	and	used	 to	 predict	 tumour	 behaviour,	 response	 to	 treatment,	 and	 survival,	 which	 can	 help	 in	making	management	decisions.	Texture	analysis	is	essentially	an	image	processing	algorithm	to	extract	and	quantify	tumour	heterogeneity.	Heterogeneity	comes	from	underlying	tumour	architecture,	 from	 noise	 due	 to	 unequal	 distribution	 of	 photons,	 and	 from	 other	 technical	factors	such	as	peak	kilovoltage,	use	and	type	of	intravenous	contrast	material,	rate	of	injection.	Texture	analysis	studies	several	textural	parameters	of	the	tumour,	sometimes	by	using	filters	to	focus	on	areas	of	variable	size	in	an	attempt	to	enhance	true	tumour	heterogeneity	while	reducing	the	effect	of	photon	noise.	Heterogeneity	is	quantified	by	using	parameters	such	as	skewness	 (a	 measure	 of	 pixel	 symmetry),	 kurtosis	 (measure	 of	 “pointedness”	 of	 the	 pixel	distribution	curve),	and	entropy	(measure	of	texture	irregularity)	[30,31]		In	a	report	it	has	been	shown	that	tumour	heterogeneity	is	an	independent	factor	associated	with	time	to	progression	of	metastatic	RCC	treated	with	targeted	therapy	and	can	potentially	serve	as	a	predictive	imaging	biomarker	of	response	[31].	Another	report	has	suggested	greater	heterogeneity	of	sarcomatoid	RCC	compared	with	ccRCC	[32].		At	 present,	 there	 are	 different	 software	 and	 various	 groups	 assessed	 numerous	 texture	parameters	using	different	methods.	These	texture	parameters	need	to	be	standardized	and	validated,	 the	 software	 need	 to	 be	 optimized,	 and	 their	 generalizability	 needs	 to	 be	 tested.	Radiogenomics	and	texture	analysis	are	new	and	promising	research	fields	at	present	focused	on	the	primary	tumour;	however,	it	could	be	interesting	to	explore	the	use	of	these	new	chances	
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to	look	for	novel	non-invasive	biomarker	in	management	of	advanced	RCC	(focusing	treatment	choice	with	molecular	targeted	agents,	detection	or	prediction	of	response	or	progression).				
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2	–	Experimental	Section		
First	Part	
Role	of	MRI	DWI	sequences	in	the	evaluation	of	early	response	to	neo-
angiogenesis	inhibitors	in	metastatic	renal	cell	carcinoma	
With	contribution	of	Prof.	A.	Vanzulli	,	Dr.	R.	Ricotta	(ASST	grande	Ospedale	Maggiore	Niguarda	Ca’	Granda,	Milano)		
Introduction	Neo-angiogenesis	is	crucial	for	growth	and	spread	of	cancer.	Among	all	factors	involved,	the	Vascular	Endothelium	Growth	Factor	 (VEGF)	 is	 the	key	point	of	 this	process,	 functioning	as	target	of	treatment	for	many	tumours.	Therapies	with	molecular	target	are	characterized	by	specificity,	low	toxicity	and	personalization.	Metastatic	renal	cell	carcinoma	is	nowadays	widely	treated	with	VEGF	and	VEGF-receptor	inhibitors,	showing	substantial	antitumor	activity	and	prolonged	median	progression-free	survival	[1,2].	Nevertheless,	it	is	still	not	clear	why	some	patients	don’t	respond.		On	the	other	hand,	Response	Evaluation	Criteria	in	Solid	Tumours	(RECIST	1.1)	has	been	widely	used	to	assess	tumour	response,	but	these	criteria	are	based	on	morphological	evaluation	of	changes	 in	 gross	 tumour	 size	 and	 they	were	 primarily	 designed	 to	 control	 cytotoxic	 drugs	effect.	New	target	agents	may	alter	vascular	supply	and	induce	changes	in	vascularization	of	lesions	before	 inducing	volume	reduction;	 finally,	 their	effect	cannot	be	totally	evaluated	by	RECIST	1.1	[3]	and	new	treatment	response	criteria	to	evaluate	the	effect	of	target	agents	are	needed.		
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Recent	MRI	 studies	 have	 focused	 on	 assessment	 of	 functional	 alteration	 due	 to	 therapeutic	response	in	RCC	treated	with	angiogenesis	inhibitors.		DCE-MRI	has	been	widely	explored	 in	pre-clinical	and	clinical	 studies	 to	assess	 response	 to	angiogenesis	inhibitors	[4].	DWI	has	the	potential	to	explore	microstructural	information	and	cell	membrane	 integrity	and	extracellular	space.	From	previous	studies	 it	 is	known	that	cell	lysis	and	necrosis	determine	increase	of	water	diffusion	and	consequent	increase	in	ADC	values	[5].		The	ability	of	DWI	to	identify	early	therapeutic	effects	of	angiogenesis	inhibitors	may	be	of	great	help	in	assessing	whether	treatment	is	effective	or	not.	Therefore,	the	objective	of	our	study	was	to	look	for	DWI	parameters	able	to	identify	patients	with	metastatic	renal	cell	carcinoma	who	would	not	benefit	from	target	therapy	(angiogenesis	inhibitors	e.g.	Sorafenib	and	Sutent)	in	patients	with	end	stage	clear	cell	renal	cell	carcinoma	(ccRCC).	RECIST1.1	was	assumed	as	Reference	Standard.		 	
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Objective	of	the	Study		Our	 objective	 was	 to	 explore	 ADC	 (quantitative	 parameter	 of	 DWI	 MRI	 sequencese)	 as	 a	possible	biomarker	of	treatment	response	to	target	agents.	In	particular	we	focused	on	target	VEGF	–	VEGF-R	inhibitors	(sunitinib	&	sorafenib)	used	to	treat	patients	with	metastatic	renal	cell	carcinoma	(stage	IV),	considering	RECIST	1.1	as	reference	standard		 	
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Material	and	Methods	
Patients	Selection	and	Study	Protocol	Our	prospective	study	was	approved	by	the	Institutional	Review	Board	and	informed	consent	was	obtained	from	each	patient.		From	May	2013	to	May	2014	consecutive	patients	with	histological	proven	clear	cell	Renal	Cell	Carcinoma	(ccRCC)	and	metastatic	disease	(Stage	IV)	were	enrolled.	Exclusion	criteria	were	(i)	patients	 enrolled	 in	 other	 clinical	 trials	 (ii)	 patients	 already	 treated	 with	 angiogenesis	inhibitors,	(iii)	any	contraindication	to	MRI.	Inclusion	criteria	were	(i)	patients	eligible	to	start	angiogenesis	inhibitors;	(ii)	with	at	least	1	target	measurable	lesion;	(iii)	measurable	lesions	at	MRI	examinations	(>2.5	cm).	We	first	select	43	patients,	but	2	of	them	were	excluded	because	they	 have	 been	 already	 treated	with	 angiogenesis	 inhibitors,	 1	 was	 taking	 part	 of	 another	clinical	 trial,	 1	 patient	 didn’t	 have	 a	 good	 target	 lesion,	 while	 1	 patient	 suffered	 from	claustrophobia.	 Therefore	 38	 patients	 were	 candidate	 to	 start	 angiogenesis	 inhibitors	 and	underwent	1,5T	MRI	examination	with	multiple	b-values	DWI	sequences	(0,40,200,300,600)	with	the	following	time-line	schedule:	t0	MRI,	within	one	week	before	treatment;	t2,	2	weeks	after	first	day	of	therapy	and	t8	after	8	weeks	from	treatment	beginning.		During	protocol	we	had	to	exclude	other	5	patients	for	several	reasons:	2	because	of	lacking	of	imaging	follow-up;	1	because	baseline	MRI	was	not	qualitative	adequate;	2	because	of	too	small	lesion	at	t8	evaluation,	not	adequate	for	ADC	measure.		Finally,	33	patients	with	38	lesions	had	complete	data	for	comparative	evaluation.		Figure	1	shows	a	flowchart	of	patient	population	and	study	protocol.	Before	treatment	and	after	8	weeks	of	therapy	all	patients	undergone	whole-body	CECT,	for	staging	reasons.	All	patients	were	finally	restaged	classifying	effectiveness	of	treatment	with	RECIST	1.1	criteria,	and	then	subjected	to	follow-up.	Outcome	data	were	available	for	OS	with	a	follow-up	period	of	34	months	(range	8.3–39.8	months).		
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Four/33	patients	were	treated	with	Sorafenib,	29/33	with	Sunitinibe.		In	Table	1	are	shown	clinical	characteristics	of	study	population.	
MRI	Examination	and	Imaging	Post-Processing	All	the	examinations	were	performed	on	clinical	1.5-T	MRI	scanners	(Gyroscan	Intera	and	ACS-NT,	1.5	T;	Philips	Healthcare,	Best,	the	Netherlands;	gradient	system:	maximum	amplitude	30	mT/m,	maximum	slew	rate	150	T/m/s)	employing	a	commercially	available	8-element	phased	array	surface	receiver	coil	with	the	patient	in	supine	position.	The	same	MRI	scanner	was	used	in	each	patient,	for	baseline	and	follow	up	MRI	examinations:	Baseline	MRI	(t0)	was	performed	at	a	mean	of	3	days	(range	0	–	7	days)	before	day	1	of	the	first	day	of	target	therapy	assumption;	MRI	after	2	weeks	of	therapy	(t2);	MRI	after	8	weeks	of	therapy	(t8).		Before	 DWI,	 unenhanced	 T1	weighted	 gradient	 echo	 (TR=211	ms;	 TE=	 5ms,	 FOV	 350	mm,	matrix	256x144,	SENSE	factor	2,	section	thickness	8	mm)	and	T2-	weighted	fast	spin-echo	(TR=	1600	ms,	TE=100	ms,	flip	angle=	80°,	FOV	350	mm,	matrix	384x196,	SENSE	factor	2,	section	thickness	8	mm)	axial	sequences	were	acquired.		The	 DWI	 sequences	 consisted	 of	 2	 axial	 free	 breathing	 single-shot	 spin-echo	 echo-planar	imaging	variant	with	2	different	train	of	b-values	(b0-40-300	and	b0-200-600).	Diffusion-weighted	signal	decay	is	commonly	analysed	using	the	mono-exponential	model	on	a	voxel	by	voxel	basis	with	an	implemented	algorithm	according	to	the	following	equation:		 	 	 	 ADC	(mm2	s-1)	=	[ln(S0Sb)]/b	where	Sb	is	the	MRI	signal	intensity	with	diffusion	weighting	b,	S0	is	the	non-diffusion	weighted	signal	intensity.	ADC	 value	 was	 calculated	 drawing	 ROIs	 on	 3	 different	 planes,	 considering	 the	 maximum-diameter-plane	and	the	one	upper	and	below,	separately	for	all	b	values	(b=	40,	200,	300,	600).	All	measurements	were	done	separately	by	2	blinded	operators	with	5	years	and	more	then	10	years	of	experience	in	MRI.	
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All	 lesions	 were	 measured	 calculating	 maximum	 diameter	 (following	 called	 d=dimension)	basing	on	pre-treatment	MDCT	and	restaging	MDCT	(performed	within	5	days	from	the	t8	MRI),	and	patients	were	classified	according	to	RECIST	1.1	criteria	[3]:	- Complete	Response	(CR):	Disappearance	of	all	 target	 lesions.	Any	pathological	 lymph	nodes	(whether	target	or	non-target)	must	have	reduction	in	short	axis	to	<10	mm.	- Partial	Response	(PR):	At	least	a	30%	decrease	in	the	sum	of	diameters	of	target	lesions,	taking	as	reference	the	baseline	sum	diameters.		- Progressive	Disease	 (PD):	At	 least	 a	 20%	 increase	 in	 the	 sum	of	 diameters	 of	 target	lesions,	taking	as	reference	the	smallest	sum	on	study	(this	includes	the	baseline	sum	if	that	is	the	smallest	on	study).	In	addition	to	the	relative	increase	of	20%,	the	sum	must	also	demonstrate	an	absolute	increase	of	at	least	5	mm.	(Note:	the	appearance	of	one	or	more	new	lesions	is	also	considered	progression).	- Stable	Disease	(SD):	Neither	sufficient	shrinkage	to	qualify	for	PR	nor	sufficient	increase	to	qualify	for	PD,	taking	as	reference	the	smallest	sum	diameters	while	on	study.	Patients	were	then	followed	up	for	a	median	of	39	months	and	progression	free	survival	(PFS)	and	Overall	Survival	(OS)	ware	assessed.		
Statistical	Analysis	SPSS,	version	20.0	(Chicago,	IL)	was	used	for	statistical	analysis.	Inter-observer	agreement	was	assessed	with	Cohen’s	Kappa	(k	£	0.40	poor	agreement,	k	=	0.40	–	0.75	good	agreement,	k	³	0.76	excellent	agreement).	Continuous	variables	are	expressed	as	mean	±	SD.	Effects	 of	 treatment	 on	 dimension	 and	 ADC	were	 explored	 comparing	 the	 same	 parameter	during	time	(t0	–t2	and	t8)	and	dividing	patients	in	group	of	response	to	treatment	(PD,	DC,	
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PR),	using	ANOVA	analysis	of	variance	inter-	group	at	the	same	time	and	intra-group	during	time	with	adjusted	F-Test.		Pearson’s	Correlation	Coefficient	r	was	used	to	assess	correlations	between	treatment-induced	changes	 in	 ADC	 and	 in	maximum	 diameter;	moreover,	 it	was	 used	 to	 look	 for	 correlations	between	changes	in	maximum	diameter	or	ADC	and	PFS	or	Overall	Survival.		A	p	value	<0.05	was	considered	as	statistically	significant.	
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Results	According	to	RECIST	1.1	criteria,	after	8	weeks	of	treatment,	patient	were	divided	in	3	different	groups	of	 response:	partial	 response	 (PR	9/33),	 stable	disease	 (SD	20/33)	and	progression	disease	(PD	4/33).	None,	as	expected,	reached	complete	response	(CR).	Average	progression	free	survival	was	272	(±252)	days,	and	overall	survival	of	877	(±705).	Maximum	 diameter	 of	 lesions	 before	 treatment	 (t0)	was	 40.2±18.2	 cm	 (mean±SD),	 after	 2	weeks	of	treatment	(t2)	38.2±19.8,	after	8	weeks	of	treatment	(t8)	35.5±20.6;	mean	ADC	value	of	lesions	at	t0,	t2	and	t8	are	shown	in	Table	2.	An	excellent	inter-observer	agreement	was	found	between	the	two	readers	for	both	maximum	diameter	and	all	ADC	measurements	before	treatment,	at	t2	and	t8	(e.g.	d	t0	k	=0,94	and	d	t8	0,91;	ADC	b600	t0	k=0.84	t8	k=0.88).	Table	2	shows	also	all	results	dividing	patients	by	group	of	response	for	size	(d)	and	ADC	at	all	b	values	at	t0,	t2	and	t8.	Differences	of	size	of	tumours	at	t0	among	the	groups	of	response	show	statistically	significant	results	 between	 PR	 and	 PD	 group	 but	 not	 statistically	 significant	 differences	 were	 found	between	PD	and	SD:	at	T0	patients	in	PD	group	have	larger	tumours	than	patients	on	PR	group	(p<0.05).	Looking	at	the	whole	population,	maximum	diameter	of	tumour	didn’t	have	significant	change	after	2	weeks	or	8	weeks	of	treatment.	But	as	expected	in	the	PD	group	we	found	an	increase	at	t8	(p<0.05).	Fig.2	shows	an	example	of	patients	with	multiple	hepatic	lesions.	ADC	values	for	PD,	SD,	PR	groups	are	graphically	shown	in	fig.3,	fig.4.	The	differences	among	the	groups	of	response	at	t0	is	always	valid	at	all	b	values.	Interesting	results	are	found	at	t0:	comparing	the	3	different	groups	at	t0,	values	from	b40	ADC	resulted	low	for	PD,	intermediate	for	DC	and	high	for	PR	(fig	4).		
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PR	group,	as	compared	to	SD	or	to	PD	showed	higher	t0	ADC	values	at	b40	(significant	different	p<0.05):	we	can	assess	that	more	vascularised	lesions	are	more	responsive	to	treatment.		PD	group	have	significantly	lower	ADC	values	then	both	other	groups,	at	t0,	t2	and	t8,	for	all	b-values	except	for	b40	at	t8	(p<0.05).	ADC	at	b40	patients	with	PR	(group	of	“responders”)	showed	a	previous	decrease	of	mean	values	(t2)	and	a	following	increase	after	8	weeks,	with	values	significantly	different	but	lower	than	t0.	ADC	at	b40	in	“non-responders”	(PD)	shows	in	contrast	a	significant	increase	after	2	weeks	and	a	following	reduction,	with	statistically	significant	higher	values	than	t0.		ADC	at	b200,	b300	and	b600	show	some	changes	in	all	groups	of	response,	but	this	seems	not	to	have	a	univocal	trend	of	change	useful	to	differentiate	responders	from	non-responders.	Correlations	of	PFS	and	OS	with	all	parameters	were	calculated,	some	of	them	poor	and	not	statistically	significant	(Table	3).	However,	some	results	were	interesting:		- First	 of	 all,	 size	 of	 lesions	 at	 t0	 doesn’t	 correlate	 significantly	 with	 PFS	 or	 OS	(respectively	r=0,14	and	r=0,29	for	maximum	diameter);	- ADC	 t0	 b40	 showed	 better	 results	 than	 dimension	 and	 the	 best	 result	 of	 significant	correlation	with	overall	survival	(respectively	with	PFS	and	OS	r=0,30	and	r=0,62	for	ADC	b40);	- ADC	 t0	 at	 the	 other	 b-values	 shows	 no	 significant	 results,	 but	 a	 trend	 of	 positive	correlation	as	compared	to	d	t0,	in	some	occasion	even	better	than	d	(e.g.	b600	&	PFS	r=0,32;	b300	&	OS	r=0,34);	- Changes	in	ADC	b40	(expressed	as	percent	of	changes	from	t0	to	t2	and	from	t0	to	t8)	have	some	interesting	inverse	correlations	with	PFS	and	OS;	the	correlation	with	OS	is	slightly	higher	for	ADC	than	for	dimensional	criteria	(respectively	for	%DADC	t0-t2	and	%DADC	t0-t8	r=-0,44	and	r=-0,42;	%Dd	t0-t2	and	%Dd	t0-t8	r=	-0,11	and	r=-0,39):	changes	
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of	 ADC	 b40	 after	 only	 2	 weeks	 of	 treatment	 achieve	 and	 slightly	 overcome	 the	dimensional	criteria	(either	expressed	as	%Ddt0-t2	or	%Ddt0-t8)	in	predicting	overall	survival;	- Surprisingly	 very	 low	 correlations	with	 PFS	 and	OS	were	 found	 looking	 at	 b600	ADC	changes	at	t2,	while	after	8	weeks	(t8)	a	slight	positive	correlation	was	found	between	changes	of	ADC	and	PFS	(r=0.36).	
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Discussion	Angiogenesis	is	essential	for	the	progression	of	all	solid	tumours,	and	angiogenesis	inhibition	remains	a	promising	approach	in	cancer	therapy.	The	antiangiogenic	agent	we	used,	sorafenib	and	sunitinib,	are	orally	active	multi-kinase	inhibitors	with	effects	on	VEGF	receptors,	platelet-derived	growth	factor	receptors	and	tyrosine	kinase	[6].	They	are	 currently	approved	 for	advanced	hepatocellular	 carcinoma	and	RCC	and	has	been	shown	to	have	significant	clinical	activity:	the	life	expectancy	of	RCC	patients	has	been	extended	to	over	30	months	 [7];	moreover,	 it	has	been	shown	prolonged	progression-free	survival	 in	patients	with	metastatic	RCC	in	whom	previous	systemic	therapy	had	failed	[1,2]		However,	a	significant	portion	of	patients	with	advanced	RCC	inevitably	develop	resistance	to	angiogenesis	inhibitors	and	relapse,	likely	for	a	mechanism	derived	from	a	non-VEGF-mediated	angiogenesis	escape	[8].		The	possibility	to	determine	the	development	of	VEGF-inhibitors	resistance	at	an	early	time	point	is	very	important,	since	these	patients	can	be	shifted	to	second	and	third	line	therapies.	In	particular	this	is	important	for	patients	who	can	benefit	from	new	immunotherapy	agents.		Traditionally	response	assessment	in	cancer	patients	was	found	on	size-	based	tumor	response	criteria	and	revised	RECIST	criteria	are	the	most	commonly	used	method	for	RCC	(RECIST	1.1).		However,	limitations	of	its	use	in	modern	RCC	treatment	are	known,	and	include	lack	of	early	indicators	 of	 response,	 lack	 of	 validation	 for	 use	 in	 novel	 targeted	 agents,	 and	 exclusion	 of	advanced	imaging	techniques	information	[44]		In	the	other	hand	it	is	crucial	to	find	a	ready	to	use,	simple,	repeatable	and	not	invasive	way	to	select	patients	potentially	non-responders	before	or	at	the	very	beginning	of	therapies,	because	RECIST	criteria	(with	1.1	version)	are	by	now	not	enough.	Use	of	contrast	media,	even	if	seems	to	be	interesting	(but	far	to	be	perfect)	in	DCE-	MRI	(quantitative	parameters	such	as	Ktrans;	ve)	[10,11],	is	not	free	from	risks,	especially	in	patients	with	chronic	renal	insufficiency,	since	the	
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exam	has	to	be	repeated	at	 least	every	2	weeks	during	the	first	cycles	of	target	therapies	to	possibly	select	early	non-responders.	CT	texture	analysis	is	a	relatively	new	tool	for	exploring	new	image	characteristics	based	on	pixel	HU	and	histogram	statistical	analysis	of	a	ROI	[12,13];	it	has	good	potential,	but	it	hasn’t	been	used	for	assessing	RCC	response	to	target	therapy	yet.		DWI	and	ADC	maps	can	be	interesting	in	this	field,	because,	excluding	patients	with	absolute	contraindications	 on	 performing	MRI,	 it	 is	 a	 safe,	 repeatable	 and	 fast	method,	 that	 doesn’t	expose	patients	to	any	particular	risk.	Therefore,	 we	 investigated	 the	 feasibility	 of	 DWI	 in	 monitoring	 early	 tumour	 response	 to	sorafenib	 or	 sunitinib	 in	 patients	with	metastatic	 clear	 cell	 Renal	 Cell	 Carcinomas	 (ccRCC),	looking	for	a	parameter	(ADC)	potentially	able	to	predict	response	to	angiogenesis-	inhibitors,	before	starting	treatment	or	early	after	day	1.	RECIST	1.1	criteria	were	considered	the	reference	standard	for	comparison.		The	application	of	this	MR	technique	to	RCC	after	angiogenesis	inhibitors	treatment	has	already	been	attempted	in	few	articles.	Desar	et	All	[14]	evaluated	the	mean	ADC	values	within	a	single	slice	through	the	primary	renal	tumour	at	 three	 time	points	 (baseline,	day	3	and	day	10	of	 the	 first	 treatment	cycle)	 in	 ten	patients	 treated	with	 sunitinib.	 They	 demonstrated	 chemotherapy-related	 changes	 in	mean	ADC,	which	were	attributed	to	cellular	swelling	at	day	3	(increased	mean	ADC)	 followed	by	tissue	 dehydration	 by	 day	 10	 (reduction	 in	 mean	 ADC	 compared	 with	 day	 3).	 These	 ADC	changes	did	not	correlate	with	DCE-MRI	parameters	or	response	measures	(outcome)	in	their	patient	group.	Bharwani	 et	 All	 [15]	 evaluated	 DW-MRI	 of	 26	 patients	 with	 metastatic	 RCC	 treated	 with	sunitinib	 before	 and	 after	 3	 cycles,	 generating	whole-tumour	 apparent	 diffusion	 coefficient	(ADC)	maps	and	histograms.	They	showed	that	patients	with	a	greater	proportion	of	tumour	lying	below	the	25th	percentile	point	of	the	whole-tumour	ADC	histogram	(a	greater	proportion	
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of	 restricted	 tissue)	 at	 t0,	 had	 reduced	 survival.	 In	 addition,	 patients	 with	 a	 greater-than-median	positive	change	in	AUClow	(i.e.,	an	increase	in	the	proportion	of	restricted	tissue)	had	reduced	survival,	whereas	those	with	a	decrease	in	AUClow	had	prolonged	survival.	These	seems	to	 be	 quite	 interesting	 results,	 but	 the	method	 is	 complicated	 and	 not	 easily	 and	 routinely	reproducible.	Looking	at	other	solid	tumours	Orton	et	All	[16]	recently	evaluated	diffusion	MR	imaging	of	metastatic	 abdominal	 and	 pelvic	 tumours	 in	 patients	 treated	 with	 VEGF-inhibitors,	 using	alternative	attenuation	model.	They	found	significant	increase	in	the	diffusion	coefficients	from	all	models	at	day	28	but	not	at	day	7.	They	also	observed	weak	correlations	between	DW-MRI	changes	and	volume	changes.	That’s	why	we	focused	on	a	practical	approach	to	the	ADC	evaluation,	trying	to	understand	if	we	can	find	an	outcome	predictor	in	the	simplest	way	of	calculating	ADC.	This	is	the	reason	why	we	decided	to	perform	free-breathing	DWI	sequences,	no	contrast	agents,	and	a	post	processing	2D	ROI	evaluation,	even	knowing	the	limitations	of	the	method.	Results	 show	 that	 patients	 with	 early	 progression	 (PD	 at	 t8)	 have	 significantly	 lower	 ADC	values	 than	PR	or	DC	 every-time	 (t0,	 t2,	 t8).	We	 could	 explain	 this	 result	 saying	 that	 these	patients	have	lesions	with	more	necrosis,	less	vascularization	and	more	cellularity	(low	ADC	values	at	b40-b600)	and	they	don’t	respond	to	angiogenesis	inhibitors.	This	is	quite	interesting	and	if	confirmed	by	other	Authors	can	become	a	biomarker	of	potentially	lack	of	response	to	target	agents	before	starting	target	therapies.			Changes	 in	 ADC	 after	 therapy	 surprisingly	were	 confusing	 and	without	 a	 univocal	 trend	 in	comparison	with	previous	studies.	But	looking	at	the	graphic	of	comparison	of	the	3	group	of	response	we	can	say	 that	 in	our	cohort	of	patients	 the	single	measure	at	 t2	or	 t8	has	not	a	significant	meaning	but	the	change	of	ADC	(b40)	at	t2	as	compared	to	t0	(delta	t0-	t2)	has	good	
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potential	to	distinguish	patients:	patients	that	respond	have	an	early	reduction	of	ADC,	stable	patients	have	no	reduction,	while	patient	with	early	progression	have	a	paradoxical	increase	of	ADC.	Caution	to	interpret	these	data	is	mandatory,	since	our	best	results	comes	from	very	low	b	values,	in	which	effects	of	microscopic	perfusion	and	diffusion	are	similarly	contributing	to	the	 grey-scale-encode	 intensity	 of	 each	 voxel,	 and	 so	 can	 be	 considered	 as	 a	 “perfusion	surrogate”	rather	than	diffusion	parameter.	We	didn’t	look	for	a	cut	off	value	because	of	the	small	number	of	patients.	Moreover,	it	is	difficult	to	talk	about	precise	values	in	ADC,	because	they	are	machine	dependant,	sequence	dependent	and	 patient	 dependent.	 Anyway	 the	 trend	 is	 interesting	 and	 probably	 giving	 the	 same	MRI	machine	and	the	same	pathology	it	will	be	possible	in	the	future	to	identify	precise	values.	Looking	at	outcome	parameters,	we	had	enough	data	to	correlate	our	ADC	parameters	and	PFS	or	OS.	First,	interestingly	PFS	correlate	with	OS	in	our	cohort	of	patients.	It	is	known	that	patients	with	metastatic	renal	cell	carcinoma	at	the	beginning	start	responding	to	the	VEGF-inhibitors,	but	sooner	or	later	they	relapse.	This	is	due	to	molecular	mechanism	of	resistance,	with	activation	of	new	pat-ways	of	regulation	of	angiogenesis.	Literature	says	that	the	time	to	new	progression	is	not	necessarily	correlated	with	final	outcome	[17].	In	our	group	of	patients,	we	found	good	correlation	of	PFS	with	OS,	highlighting	that	the	sooner	our	patients	relapse,	the	sooner	they	die.		Moreover,	early	cellular	swelling	and	decreased	vascularity	induced	by	therapy	after	2	weeks	may	lead	to	a	transient	decrease	in	ADC	value	in	patients	that	respond	effectively	to	treatment	(PR	group).		At	t0	there	is	a	better	correlation	between	PFS	&	ADC	(b40)	then	PFS	&	dimensional	criteria.	This	is	important,	because	confirm	that	lesions	with	higher	ADC	b40,	having	higher	vascularity,	have	more	 chance	 to	 respond	 to	 VEGF	 inhibitors	 and	 confirm	 that	 dimensional	 criteria	 of	
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response	evaluation	(RECIST),	with	the	advent	of	target	therapy,	are	not	anymore	as	useful	as	in	the	past	era	of	cytotoxic	conventional	chemotherapy.		There	are	some	limitations	to	the	present	study,	the	first	is	the	small	group	of	patients.	We	had	a	small	number	of	patients	in	PD	group	and	this	could	have	biased	our	results.	Secondly,	we	analysed	 lesions	differently	 located	 in	abdomen,	mediastinum	and	pelvis,	 knowing	 that	 this	could	affect	DWI	and	ADC	measurements.		
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Conclusion	Nowadays,	in	the	era	of	target	therapy,	it	is	crucial	to	select	patients	who	potentially	can	benefit	of	target	agents.	We	have	to	look	at	possible	new	treatment	options	and	to	cost/benefit	ratio,	as	well	as	avoid	patient’s	subject	to	unnecessary	side	effects	related	to	the	treatment.	ADC	at	t0	may	help	selecting	patients	with	promising	good	response	to	angiogenesis	inhibitors.	Moreover,	at	t0	and	at	t2	ADC	has	the	potential	to	select	patients	who	wouldn't	benefit	from	angiogenesis	 inhibitors.	 These	 results	 come	 from	 low	 b-values	 and	 confirm	 that	 pre-assessment	 of	 grade	 of	 vascularity	 of	 the	 lesion	 can	 be	 of	 great	 help	 in	 treatment	 decision	making.	DWI	 has	 the	 potential	 role	 to	 identify	 patients	whose	 tumour	wouldn’t	 benefit	 from	 target	therapy,	adding	a	value	(ADC)	to	other	imaging	(e.g.	DCE-MRI,	texture	imaging)	and	genomics	parameters	 (e.g.	 miRNA)	 in	 a	 hypothetic	 multi-parametric	 analysis,	 with	 a	 possible	 future	radiogenomics	approach.		 	
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Figure	1	
	Fig.	1	Flowchart	of	patients	and	protocol	of	the	study		 	
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Table	1	
Patient	demographics	and	characteristics	at	diagnosis	Number	of	patients	 33	Age	(years)	 65,7±5,8	Gender	 Male	 22	Female	 11	Lesions	 Adrenal	 7	Liver	 9	Peritoneum	 2	Retroperitoneum	 4	Ab.	lynphnodes	 5	Lung	 1	Mediastinum	lynphnodes	 2	Soft	tissue	 3	Bone	 1	Kidney	 4	Treatment	 Sorafenib	 4	Sunitinib	 29	Line	of	treatment	 1	 20	2	 13	MSKCC	prognostic	risk	Intermediate	 23	Poor	 10	Clear	cell	tumour	grade	 		 		 		1-2	 	9	3-4	 	24	Median	OS,	months	 29	(±23)		Median	PFS,	months	 	9	(±8)	Abbreviations:	MSKCC=	Memorial	Sloan-Kettering	Cancer	Centre;	OS=overall	survival;	PFS=progression-free	survival		Tab.	1	Demographics	and	characteristics	of	patient’s	population		 	
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Table	2	
N=33	 ADC	b40	 ADC	b200	 ADC	b300	 ADC	b600	 d	
t0	 4,05±1,14	 2,25±0,45	 2,05±0,36	 1,72±0,19	 40,2±18,2	
t2	 3,69±1,20	 2,00±0,40	 1,96±0,29	 1,60±0,19	 38,2±19,8	
t8	 3,55±1,07	 1,96±0,32	 1,90±0,28	 1,56±0,15	 35,5±20,6	a)	
PR	 ADC	b40	 ADC	b200	 ADC	b300	 ADC	b600	 d	
t0	 6,85±1,17	 2,14±0,37	 2,79±0,45	 1,93±0,17	 38,5±14,8	
t2	 3,86±1,46	 2,51±0,35	 2,12±0,27	 1,84±0,15	 32,8±16,8	
t8	 4,89±1,26	 1,87±0,37	 2,51±0,30	 1,59±0,16	 20,4±4,2	b)	
SD	 ADC	b40	 ADC	b200	 ADC	b300	 ADC	b600	 d	
t0	 3,56±1,15	 2,37±0,50	 1,96±0,34	 1,74±0,19	 37,8±26,3	
t2	 3,59±1,08	 1,89±0,41	 1,99±0,29	 1,49±0,20	 37,5±25,6	
t8	 3,17±1,02	 2,06±0,31	 1,77±0,27	 1,63±0,15	 35,4±23,0	c)	
PD	 ADC	b40	 ADC	b200	 ADC	b300	 ADC	b600	 d	
t0	 1,73±0,98	 1,64±0,26	 1,29±0,32	 1,14±0,22	 44,5±13,4	
t2	 4,10±1,52	 1,24±0,25	 1,44±0,30	 0,97±0,12	 53,0±22,6	
t8	 3,43±1,08	 1,21±0,29	 1,32±0,30	 0,82±0,15	 57,5±27,6	d)	Tab.2	ADC	median	values	and	dimensions	(d,	cm)	at	different	b	values	during	follow-up.	a)	all	patients	are	considered	together;	b)	Partial	Response	group	(PR);	c)	Stable	Disease	group	(SD);	c)	Progression	Disease	group	(PD)		 	
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Figure	2	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2	Example	of	ADC	maps	elaborated	from	DWI	at	b40	(upper)	and	at	b600	(lower)	in	a	patient	 with	 multiple	 hepatic	 lesions.	 Lesions	 are	 slightly	 hyperintense.	 ROI	 are	 manually	drawn	on	the	lesions	(e.g.	2	lesions	on	S7)	and	Mean	ADC	value	is	provided	
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Figure	3	
	
	
a)	
	
	
b)	
	
	
c)	
	
Fig.	3	of	ADC	for	all	b	values	in	a)	partial	response	group;	b)	stable	disease	group;	c)	progression	disease	group	 	
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Figure	4	
	
	
	
	
	
	
Fig.4	Comparison	of	group	of	response:	ADC	b40	(a)	and	b600	(b)	at	t0,	t2,	t8.		 	
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Table	3		
dimension	 PFS	 OS	
∆	(%)	d	t0-t2	 -0.33*	 -0.11	
∆	(%)	d	t0-t8	 -0.58*	 -0.39*	
d	t0	 0.14	 0.29	a)	
b40	 PFS	 OS	
∆(%)	ADC	t0-t2	 -0.26	 -0.42*	
∆(%)	ADC	t0-t8	 -0.16	 -0.44*	
ADC	t0	 0,30	 0.62*	
ADC	t2	 0,18	 0.20	
ADC	t8	 0.29	 0.29	b)	
b300	 PFS	 OS	
∆(%)	ADC	t0-t2	 -0.08	 -0.7	
∆(%)	ADC	t0-t8	 -0.02	 0.04		
ADC	t0	 0.23	 0.34	
ADC	t2	 0.19	 0.29	
ADC	t8	 -0.04	 -0.02	c)	
b600	 PFS	 OS	
∆(%)	ADC	t0-t2	 -0.12	 -0.15	
∆(%)	ADC	t0-t8	 0,36*	 -0.9		
ADC	t0	 0,32	 0.19	
ADC	t2	 0,23	 0.33	
ADC	t8	 0.17	 0.10	d)	
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Tab.	3	Pearson	Correlations	between	Dimensional	criteria	(a)	or	ADC	(b,	c,	d)	with	Progression	Free	 Survival	 and	Overall	 Survival.	 *	 indicates	 statistically	 significant	 results	 (p>0.05).	 Best	results	are	found	for	ADC	at	b40	(b)			
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Second	Part	
CT	Texture	Analysis	in	Clear	Cell	Renal	Cell	Carcinoma:	a	Radiogenomics	
Prospective	
With	contribution	of	Prof.	V.	Petrozza(1),	Dr.	F.	Fazi	(2)	,	Dr.	G.	Bellotti(3),	Dr.	S.	Badia	(3),	Prof.	A.	Laghi	(3)	(1) Pathology	Unit,	ICOT,	Department	of	Medico-Surgical	Sciences	and	Biotechnologies,	Sapienza	University	of	Rome,	Latina	 04100,	 Italy;	 vincenzo.petrozza@uniroma1.it(2)	 Department	 of	 Anatomical,	 Histological,	 Forensic	 &	Orthopaedic	Sciences,	Section	of	Histology	&	Medical	Embryology,	Sapienza	University	of	Rome,	Rome	00161,	Italy;(3)	Università	Roma	Tre	(4)	ICOT	Department	of	Radiology	
	
Introduction	Clear	cell	Renal	cell	carcinoma	(ccRCC)	is	a	common	group	of	chemotherapy-resistant	tumour	representing	2%–3%	of	adult	malignancies,	with	the	clear	cell	histotype	(ccRCC)	accounting	for	80%–90%	of	all	RCCs	 [1].	 It	 is	 the	 third	most	 common	urological	 cancer	after	prostate	and	bladder	 cancer,	 but	 it	 has	 the	 highest	 mortality	 rate	 (about	 40%)	 [2].	 Deeper	 molecular	characterization	could	 improve	ccRCC	diagnosis	and	management,	 as	well	 as	prognosis	and	treatment	choice.	In	this	scenario	miRNA	are	emerging	as	interesting	biomarkers	for	several	tumours	[3]	[4].	They	are	small	noncoding	RNAs	which	have	an	important	role	in	the	regulation	of	carcinogenesis	pathways:	pathological	tissue	expresses	miRNAs	in	a	different	way	compared	with	corresponding	normal	tissue,	regulating	important	breakpoints	during	carcinogenesis	[5]	[6].	Recently	they	have	been	addressed	as	part	of	ccRCC	tumorigenesis	and	progression	[7]	[8],	so	 that	 a	 “miRNA	 signature”	 in	 ccRCC	 has	 been	 described	 and	 significantly	 correlated	with	
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patient	 outcome	 [9]	 [10].	 miR-21	 and	 miR-210	 as	 well	 as	 miR-185	 and	 miR-221	 showed	functional	relevance	for	ccRCC	tumorigenesis	[11]	[12].	The	grade	of	expression	of	miRNAs	is	cancer-	and	tissue-specific	and	often	it’s	in	accordance	with	tumour’s	grading;	for	this	reason	expression	profile	of	miRNA	in	ccRCC	can	be	helpful	to	differentiate	healthy	 from	pathological	 tissue,	 to	 identify	 slightly	differentiated	 cancers	 that	would	 otherwise	 be	 undetermined	 with	 the	 use	 of	 conventional	 histology	 and	immunohistochemistry	and,	 lastly,	 to	 recognize	 tumours	with	different	histotype	within	 the	same	organ	[5].	Going	 further	we	 tried	 to	 understand	 if	 the	 “ccRCC	miRNA	 signature”	 had	 a	 corresponding	phenotype	in	radiological	examinations	(radio-phenotype),	looking	for	a	connection	between	genotype	and	radio-phenotype,	in	a	radiogenomics	point	of	view.	An	emerging	potentially	useful	imaging	biomarker	is	CT	tumour	texture	analysis	(CTTA),	which	has	shown	promising	results	in	predicting	patient	outcome,	overall	survival	and	response	to	therapy	for	multiple	RCC	histotypes.	[13]	[14]	CTTA	is	a	quantitative	technique	that	allows	to	characterize	the	heterogeneity	of	a	lesion	inside	a	 region	of	 interest	 (ROI)	by	analysing	 the	distribution	and	relationship	of	pixel	grey-levels	using	both	unfiltered	and	frequency	filtered	images,	deriving	quantitative	texture	parameters	based	on	attributes	of	the	pixels	and	the	image	histogram.[13].		 	
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Objective	of	the	Study		To	the	best	of	our	knowledge,	none	has	investigated	a	possible	correlation	between	CT	texture	parameters	and	miRNA	expression	in	ccRCC.	For	 this	 reasons,	 the	 aim	 of	 this	 study	was	 to	 investigate	whether	 quantitative	 parameters	obtained	from	CTTA	correlate	with	different	grade	of	expression	of	mi-RNA	in	patients	affected	by	clear	cell	Renal	Cell	Carcinoma	(ccRCC).		 	
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Material	and	Methods	This	 retrospective,	 single-centre,	 Health	 Insurance	 Portability	 and	 Accountability	 Act-compliant	study	was	approved	by	the	Institutional	Review	Board	and	informed	consent	was	obtained.	No	authors	are	employees	of	or	consultants	for	industry	or	had	control	of	inclusion	of	any	data	and	 information	 that	 could	 represent	 a	 conflict-of-interest.	 There	was	 no	 industry	 support	specifically	for	this	study.	
Study	Population	Figure	1	portrays	the	subjects’	accrual	flowchart,	which	is	based	on	the	Standards	for	Reporting	of	 Diagnostic	 Accuracy	 (STARD)	 initiative.	 	 Forty-five	 consecutive	 patients	who	 underwent	contrast	enhanced	computed	tomography	(CECT)	of	abdomen	and	pelvis	for	suspected	ccRCC	between	April	1,	2014	and	June	1,	2016,	were	primarily	included.	Clinical	 indications	for	CT	included	(i)	clinical	suspicion	for	ccRCC	cancer	based	on	the	patient’s	clinical	history	and/or	elevated	tumour	markers	levels	or	(ii)	patients	known	to	have	a	suspicious	renal	lesion	on	the	basis	 of	 the	 results	 of	 prior	 imaging	 studies,	 such	 as	 ultrasonography,	 unenhanced	 CT,	 or	magnetic	resonance	(MR)	imaging.	Subjects	were	considered	not	eligible	for	this	study	if	(i)	the	CT	 examination	 resulted	 in	 no	 kidneys	 lesions;	 (ii)	 patients	 underwent	 previously	chemotherapy,	radiotherapy	or	immunotherapy;	(iii)	too	small	lesion	for	good	CTTA	analysis	(<2	 cm),	 (iv)	 inadequate	 image	 quality	 due	 to	 either	 suboptimal	 injection	 technique,	 poor	timing	for	the	acquisition	of	the	urographic	phase,	or	deviations	from	the	routine	CT	protocol	(e.g.,	inappropriate	selection	of	kV	or	reconstruction	kernel	by	the	CT	technologist).	Basing	on	CT	and	clinical	pre-surgery	evaluations	we	could	include	35	patients,	8	of	which	were	proved	to	have	benign	lesions	(basing	on	other	imaging	evaluations,	follow	up,	percutaneous	biopsy).	Finally,	two	patients	with	suspicious	RCC	on	the	base	of	CT	characteristics	refused	biopsy	or	surgery	due	to	old	age	and	suboptimal	global	clinical	conditions.	Thirty-one	patients	underwent	
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biopsy	(5/31)	or	direct	surgery	(26/31	nephrectomy	or	tumorectomy	basing	on	tumour	size).	After	histopathological	examination	only	21	clear	cell	renal	cell	carcinoma	were	found;	one	of	them	was	not	eligible	for	the	study	because	of	no	complete	miRNA	extraction	for	tumour	and	matched	normal	tissue.		Our	final	study	population	included	20	patients	(14	males,	6	females;	mean	age	65	years	±	13,	range	35-87	years;	mean	Body	Mass	Index	(BMI)	27	kg/m2	±	4,37;	range	20,8-40,3	kg/m2)	with	20	ccRCC	suitable	for	Texture	analysis	CT	examination	and	miRNA	extraction	(Table	1).		
Hystopatological	Analysis	(RNA	Extraction	and	MicroRNA	Expression	Analysis)	Eight	samples	of	fresh	frozen	tissues	from	8	ccRCC	lesions	were	analysed	and	homogenized	by	gentle	dissociator	(Miltenyi	Biotec)	in	700	microl	of	Qiazol	(Qiagen,	Chatsworth,	CA);	RNA	was	extracted	using	manufacturer’s	instructions.		A	cohort	of	12	ccRCC	formalin-fixed	paraffin-embedded	(FFPE)	tissue	samples	from	12	patients	was	analysed.	RNA	was	extracted	using	the	miRneasyr	FFPE	kit	(Qiagen,	Chatsworth,	CA,	USA)	following	the	manufacturer’s	instructions.		For	each	sample,	a	matched	normal	tissue	sample	was	collected.	For	both	cohorts,	the	concentration	and	purity	of	total	RNA	were	assessed	using	a	Nanodrop	TM	1000	spectrophotometer	(Nanodrop	Technologies,	Wilmington,	DE,	USA).	A	quantity	of	150	ng	of	total	RNA	was	reverse	transcribed	in	8	µL	using	miScript	II	RT	kit	(Qiagen,	Chatsworth)	and	1	µL	of	cDNA	dilution	(1:4)	was	used	for	quantitative	real	time	PCR	(RT-qPCR)	experiments.	PCR	quantification	analysis	of	the	SCARNA17	SNORD61,	SNORD68,	RNU6-2	and	miRNAs	miR-21-5p,	 miR-210-3p,	 miR-185-5p,	 miR-221-3p	 and	 miR-145-5p,	 was	 performed	 using	 the	miScript	 SYBR	 Green	 PCR	 kit	 (Qiagen,	 Chatsworth)	 with	 the	 miScript	 Primer	 Assay	 Hs-SCARNA17	(#MS00014014),	SNORD61	(#MS00033705),	SNORD68	(#MS00033712),	RNU6B-2	(#MS00033740),	Hs-miR-21-5p	(#MS00009079),	Hs-miR-210-3p	(#MS00003801),	Hs-miR-
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185-5p	 (#MS00003647),	 Hs-miR-221-3p	 (#MS00003857),	 Hs-miR-145-5p	 (#MS00003528)	(Qiagen,	Chatsworth,	CA,	USA).	The	expression	analyses	of	RNU19	and	RNU66	were	performed	by	TaqMan	MicroRNA	RT	assay	and	TaqMan	MiRNAr	Assays	 (RNU19	#001003	 and	RNU66	#001002)	 (Applied	Biosystems,	Foster	City,	CA,	USA)	according	to	the	manufacturer’s	protocol.	All	reactions	were	performed	in	duplicate.	Data	were	analysed	by	quantification	relatively	to	a	standard	curve.	The	standard	curve	was	prepared	with	serial	dilutions	of	a	 reference	cDNA	obtained	 from	RNA	extracted	from	a	tumour	sample.	z-scores	were	calculated	for	all	expression	values	to	standardize	the	data.	Subsequently,	z-score	values	of	RNU66,	RNU19	and	SCARNA17	were	averaged	and	used	to	normalize	 the	expression	values	of	 each	miRNA	 in	FFPE	samples	while	 z-score	values	of	SNORD61,	SNORD68,	RNU6-2	were	averaged	and	used	to	normalize	the	expression	values	of	each	miRNA	in	fresh	frozen	samples.	
MDCT	Acquisition	Protocol	All	 scans	were	 performed	with	 a	 64-row	multiple	 detector	 computed	 tomography	 (MDCT)	scanner	 (Lightspeed	 VCT®,	 GE	 Medical	 Systems,	 Waukesha,	 WI,	 USA)	 using	 the	 following	parameters:	kV,	120;	beam	pitch,	1.375:1;	detector	configuration,	64×0.625	mm;	reconstructed	section	thickness,	1.25	mm.		A	z-axis	tube	current	modulation	was	used,	with	a	noise	index	of	28	(min/max	mA:	200/600)	which	 was	 recommended	 by	 the	manufacturer	 for	 standard	 abdominal	 CT	 in	 all	 cases.	 All	examinations	were	performed	using	a	multiphase	MDCT	protocol	(Table	2).	All	patients	received	an	average	of	120	mL	of	an	intravenous	non-ionic	contrast	medium	with	an	iodine	concentration	of	350	mg	iodine/mL	(Iomeprol®,	Iomeron	350®;	Bracco,	Milan,	Italy).	The	bolus	of	contrast	medium	was	injected	through	an	18-20	gauge	cannula	inserted	into	an	antecubital	vein	using	a	dual-chamber	peristaltic	injector	(CT	Exprès®,	Bracco,	Milan,	Italy)	at	a	flow	rate	of	3,5	mL/s.		
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All	patients	were	positioned	supine	with	head	first	on	the	scanning	table.	The	scanning	protocol	started	with	 the	acquisition	of	anteroposterior	and	 lateral	digital	 localizer	 radiographs.	The	acquisitions	of	 the	abdomen	and	pelvis	were	performed	 in	 the	cranio-caudal	direction	after	iodine	intravenous	injection	of	contrast	medium	in	arterial,	portal,	equilibrium	and	urographic	phases.		A	bolus	tracking	technique	was	used	to	minimize	the	influence	of	cardiac	output;	CM	detection	was	monitored	in	a	region	of	interest	(ROI)	placed	in	the	aorta	at	the	level	of	the	diaphragm;	the	threshold	for	the	start	of	the	scan	was	set	at	100	HU.	A	late	arterial	phase	was	acquired	18	s	after	reaching	the	threshold;	a	portal	phase	35	s	after	the	end	of	arterial	phase;	an	equilibrium	phase	was	acquired	at	120	s	after	the	end	of	portal	vein	and	urographic	phase	was	acquired	after	12	minutes.		
Image	Reconstruction	Imaging	 reconstructions	were	 obtained	 using	 40%	of	 an	 iterative	 reconstruction	 algorithm	(ASiR®,	GE	Healthcare,	Milwaukee,	WI,	USA).	Images	were	reconstructed	using	a	medium-smooth	kernel	(Q30)	at	1.25-mm	reconstructed	section	thickness	(Table	2).	
Imaging	Data	Analysis		All	analyses	were	performed	using	a	commercially	available	CTTA	research	software	platform	(Version	1.1;	TexRAD	Ltd®,	Somerset,	UK)	on	a	dedicated	workstation.	CTTA	was	performed	on	twenty	clear	renal	cell	carcinomas	(RCCs)	drawing	manually	two	different	polygonal	ROIs	at	three	different	axial	levels	in	arterial,	portal,	delayed	and	urographic	phases	(Fig.	2):	1)	into	the	lesion	 (including	 the	majority	 of	 the	 lesion	 in	 that	 plane	 and	 excluding	margins);	 2)	 in	 the	normal	parenchyma	of	the	kidney	including	cortical	and	medullar	layers.	All	images	were	reviewed,	and	slices	were	selected	by	two	readers	(radiologist	with	10	years	of	experience	and	radiology	resident	with	3	years	of	experience	on	abdominal	CT).	
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The	 technique	 consisted	 of	 a	 preliminary	 filtration	 step,	 followed	 by	 quantification	 of	 the	texture	within	the	filtered	images.		The	 filtration	 step	 comprised	 Laplacian	 of	 Gaussian	 (LoG)	 spatial	 band-pass	 filter	 used	 to	produce	 multiple	 series	 of	 derived	 images	 extracting	 and	 enhancing	 features	 at	 different	anatomical	spatial	scales;	this	resulted	in	a	series	of	derived	images	from	fine	to	coarse	texture	within	a	region	of	 interest	(ROI)	 identified	with	“spatial	scaling	 factor”	(SSF).	The	scale	was	selected	by	tuning	the	filter	parameter	between	0	and	2.0,	where	SSF1.0	indicates	fine	texture	(features	of	approximately	2	pixels	in	width),	SSF1.5,	1.8	and	2.0	indicate	degrees	of	medium	textures	(features	of	approximately	6,	8	and	10	pixels	in	width	respectively).		This	 is	 followed	 by	 quantification	 of	 statistical	 parameters	 in	 a	 histogram-based	 statistical	approach	(first,	second	or	higher	order	parameters).	The	software	output	includes:	mean	pixel	attenuation	(M,	Mean),	standard	deviation	of	the	pixel	distribution	histogram	(SD,	dispersion	from	the	mean),	entropy	(E,	irregularity	in	terms	of	randomness	of	distribution	of	pixels),	mean	of	 positive	 pixels	 (MPP),	 skewness	 of	 the	 pixel	 histogram	 (S,	 asymmetry),	 kurtosis	 (K,	sharpness)	of	the	pixel	histogram,	and	the	percentage	of	positive	pixels;	all	these	histogram	–	based	parameters	are	provided	for	each	spatial	scaling	factor.		 	
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Statistical	Analysis	All	data	were	described	as	mean	±	standard	deviation.		CTTA	was	performed	for	each	of	the	six	parameters	at	each	SSF	(in	number	of	5)	and	for	all	post-contrast	 CT	 phases	 acquired	 (i.e.	 healthy	 kidney,	 arterial	 phase,	 portal	 phase	 and	urographic	phase),	with	a	total	of	120	variables.	A	matrix	of	data	on	MatLabâ	has	been	elaborated	from	5	different	miRNAs	(miR-145-5p,	miR-185-5p,	 miR-221-3p,	 miR-21-5p,	 miR-210-3p),	 6	 texture	 parameters	 (Mean,	 Standard	Deviation,	Entropy,	Mean	of	Positive	Pixels,	Skewness,	Kurtosis)	in	5	different	spatial	scaling	factors	 (SSF0,	 SSF1,	 SSF1.5,	 SSF1.8,	 SSF2.0).	 All	 data	 were	 elaborated	 for	 normal	 kidney	parenchyma	and	for	3	different	ROIs	on	tumour	volume,	finally	producing	a	total	of	more	than	170	graphics	of	correlation.	Normality	of	each	continuous	variable	was	tested	with	Z-test.	Differences	 between	 normal	 tissue	 and	 tumour	 in	 all	 miRNA	 expression	 and	 all	 CTTA	parameters	was	assessed	using	paired	t-Student	test.	First	step	of	statistical	analysis	was	aimed	to	assess	statistically	significant	differences	between	the	2	groups	of	lesions’	samples:	formalin	fixed	(FFPE)	and	fresh	frozen	(FF).		Differences	in	the	evaluations	of	CTTA	parameters	between	the	2	operators	were	calculated	(inter-observer	agreement	with	Cohen’s	Kappa,	with	k	£	0.40	poor	agreement,	k	=	0.40	–	0.75	good	agreement,	k	³	0.76	excellent	agreement).	Secondary	all	lesions	were	evaluated	all	together,	since	no	statistically	significant	difference	in	miRNA	expression	was	found	between	the	2	groups	and	between	the	2	operators	for	CTTA.		In	 addition,	 statistically	 significant	 difference	was	 assessed	 for:	 (i)	miRNA	normal	 tissue	 vs	tumour	samples;	(ii)	CTTA	parameters	in	normal	tissue	vs	tumour	samples.		
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For	comparison	of	miRNA	vs	CTTA	parameters	was	then	used	Pearson	correlation	coefficient	(r):	r	was	interpreted	as	follows:	a	negative	value	or	less	than	0.20	indicated	poor	agreement;	a	value	of	0.21-0.40,	fair	agreement;	a	value	of	0.41-0.60,	moderate	agreement;	a	value	of	0.61-0.80,	substantial	agreement;	and	a	value	of	0.81-1.00,	almost	perfect	agreement.	For	all	comparisons,	statistical	significance	was	assumed	to	be	p	<	0.05.	All	statistical	analyses	were	performed	by	using	a	commercially-available	statistical	software	package	SPSS	version	21.0	(SPSSInc®,	Chicago,	MO).		 	
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Results	Mean	tumours’	maximum	diameter	was	4.2	cm	(±	2,38),	with	a	prevalence	of	grading	score	G2	(15/20)	pT1a	and	pT1b	(16/20)	at	histology	evaluation	(Table	1).	A	 total	 of	 twenty	 matched	 ccRCC	 and	 adjacent	 normal	 tissue	 samples	 were	 collected	 and	analysed	 for	 miRNAs	 expression.	 Interestingly,	 miR-21-5p,	 miR-210-3p	 and	 miR-221-3p	resulted	significantly	up-regulated	in	ccRCC	vs	normal	tissues	(p	<	0,05).	In	particular	the	expression	of	miR-21-5p,	miR-210-3p	and	miR-221-3p	resulted	particularly	up-regulated	 in	 tumour	 samples	 (respectively	 0.94	 ±	 0.61,	 1.57	 ±	 1.32	 and	 1.13	 ±	 0.74)	 as	compared	to	normal	tissues	(respectively	0.60	±	0.52,	1.18	±	0.94	and	0.71	±	0.33)	with	a	p	value	<	0.05;	although	miR-185-5p	did	not	show	any	statistically	significant	difference	between	tumour	and	normal	tissues,	showed	a	trend	of	expression	similar	to	miR-21-5p	and	miR-221-3p	 (p	 >	 0.05).	 Moreover,	 miR-145-5p	 expression	 resulted	 particularly	 up-regulated	 in	 few	tumour	samples	compared	to	normal	tissues,	and	down-regulated	in	others	(9/20)	however	no	statistically	significant	difference	between	ccRCC	and	normal	tissues	was	obtained	(p	>	0.05)	(Fig.	3).	No	differences	were	 found	between	the	2	operators	 in	collected	CTTA	parameters	(k=0,84).	The	analyses	shown,	were	elaborated	using	data	from	the	best	operator-results.	When	 considering	 texture	 parameters	 alone,	 differences	 between	 healthy	 and	 pathological	tissue	 within	 the	 same	 SSF	 and	 the	 same	 contrast	 phase	 were	 consistent	 and	 statistically	significant	for	the	majority	of	parameters	(entropy,	mpp,	sd	and	mean)	when	a	medium	texture	filter	setting	(SSF1	or	SSF1.5)	was	used	(p<0.05);	 for	 these	parameters	 it	has	been	shown	a	statistically	significant	difference	between	normal	tissue	ROIs	and	pathological	tissues,	in	all	contrast	phases	(Table	3).	
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Moreover,	comparing	different	contrast	phases	within	the	same	SSF	no	significant	differences	were	found	in	each	parameter	 in	particular	between	medium	filters	(SSF	1.5	–	1.8	–	2.0).	 In	specific	entropy	values	arterial	phase	in	normal	tissue	were	4.66±0.21	(SF1),	4,71±0,21	(SF1.5),	4,72±0,19	 (SF1.8),	 4,73±0,19(SF2.0);	 while	 in	 tumour	 ROI	 entropy	 was	 5.67±0.41	 (SF1),	5,76±0,40	(SF1.5);	5,79±0,39	(SF1.8);	5,80±0,40	(SF	2.0)	respectively.	miRNA	expression	in	normal	tissue	didn’t	correlate	with	any	CTTA	parameter	(p>0.05).	On	the	other	side	a	trend	of	positive	correlation	was	found	between	some	miRNA	and	some	CTTA	parameters	when	tumour	samples	were	analysed	(Table	4)	(Figure	4).	The	best	trends	were	 found	when	delta	of	 expression	 (∆)	 and	delta	of	percent	 (%∆)	of	 expression	between	healthy	tissue	and	pathological	tissue	were	used	for	the	expression	of	our	data.	When	comparing	CT	texture	parameters	and	miRNA	expression	we	found	a	dispersion	of	data	in	the	graphics	of	comparison,	showing	very	poor	agreement	with	mi-RNA	expressivity	for	most	of	the	parameters.	Interestingly	 entropy	 showed	 the	best	 results:	 for	 example,	 in	 a	non-linear	graphic	 relation	between	%∆	of	miRNA	and	entropy	in	normal	tissue	and	tumour	samples,	while	miR-210-3p	didn’t	show	any	relation	with	entropy	expression,	miR-21-5p	was	found	to	be	the	most	well-correlated	with	entropy	(arteriosus	phase,	SF1)	with	a	higher	coefficient	of	determination	(R2	is	the	proportion	of	the	variance	in	the	dependent	variable	that	is	predicted	by	the	independent	variable).	These	results	were	confirmed	using	all	SF	and	all	post-contrast	phases.	Moreover,	the	results	are	better	expressed	using	percent	Delta	of	miRNA	expression	(R2=0,06	for	miR210	and	R2=0,25	for	miR21-5p).	Analysing	 data,	we	 recognized	 4	 patients	with	 particularly	 over-expressed	miRNA	but	 only	slight	increase	of	entropy	(as	compared	to	normal	tissue):	their	texture	parameters	were	not	far	 from	 the	median	 values	 of	 the	 texture	 parameters	 of	 the	 other	 patients,	 but	miR-21-5p	expression	differ	a	lot	from	the	other	patients.	The	expression	of	miR-21-5p	in	normal	tissue	
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was,	at	contrary,	not	far	from	the	median	values	of	other	samples.	Interestingly,	excluding	them	from	the	analysis,	we	found	again	that	normal	tissue	entropy	was	not	related	with	miR-21-5p	(R2=	0,17),	while	texture	excellent	relation	of	entropy	in	tumour	samples	with	miR21-5p	was	found	(R2=	0,64	fig	4).			 	
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Discussion	Evaluation	of	a	renal	lesion	using	CT	or	MRI	sometimes	with	presumption	of	the	histotype	is	nowadays	based	on	the	radiologist’s	2D	examination	of	lesion	morphology	and	enhancement,	and	this	routinely	determines	subsequent	patient	management.	CT	and	MRI	are	the	most	used	imaging	techniques	in	the	staging	of	ccRCC	before	treatment;	however,	 this	 type	 of	 tumours	 is	 characterized	 by	 genetic,	 epigenetic	 and	 pathologic	heterogeneity,	which	makes	accurate	diagnosis	or	prognosis	prediction	difficult.		Many	efforts	have	been	done	by	radiologist	and	experts	 looking	 for	 imaging	biomarkers	 for	characterization	of	tumours	and	follow-up	during	therapies.		CTTA	allows	quantification	of	lesion	heterogeneity	based	on	the	distribution	of	pixel	intensities	within	a	ROI.	CTTA	is	a	relatively	new	tool	with	a	great	potential,	it	can	be	of	great	help	for	the	radiologist	to	better	characterize	lesions	and	to	identify	parameters	of	response	to	treatment.	However,	it	is	still	soon	to	consider	all	done.		Radiogenomics	refers	to	the	correlation	between	cancer	imaging	features	and	gene	expression:	the	most	interesting	results	are	obtained	in	onco-imaging	field.	Recently,	some	authors	have	evaluated	the	correlation	between	the	imaging	characteristics	and	molecular	features	of	malignancies.	Jain	et	al	demonstrated	that	the	clinical	features,	imaging	and	molecular	characteristics	may	provide	information	on	the	portion	of	glioblastoma	without	contrast	 enhancement	 [14].	 Correlations	 between	 genetic	 mutations	 and	 CT	 features	 were	observed	by	Karlo	et	Al	for	ccRCC	carcinoma	and	by	Rizzo	et	al	for	NSCLC	[15,	16].	Comparison	 of	 CTTA	 and	 molecular	 or	 genetics	 aspects	 of	 tumours	 has	 been	 explored	 in	colorectal	cancer	by	De	Cecco	et	Al	who	found	a	correlation	between	changes	in	kurtosis	values	and	response	to	radio-chemotherapy	in	colorectal	cancer	[17].	and	in	head	&	neck	cancer	and	NSCLC	by	Aerts	et	Al	who	constituted	a	prognostic	radiogenomics	signature	of	these	tumours	
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[18].	 Sacconi	 et	 Al	 finally	 recently	 found	 a	 correlation	 between	 EGFR	 and	 mean,	 SD	 and	skewness,	and	between	entropy	and	the	event	of	death	in	lung	adenocarcinoma	[19].	MicroRNAs	are	a	class	of	small,	noncoding	RNAs	that	play	a	key	role	on	post-transcriptional	expression	of	target	genes,	and	they	are	recently	found	to	be	a	new	class	of	genes	with	tumour-suppressor	and	oncogenic	functions	[13,	14].	In	the	field	of	urological	carcinoma,	miRNAs	are	acquiring	a	role	as	biomarkers	[20,	21,	22].	In	 particular	miRNA-21-3p	 is	 the	most	 overexpressed	 in	 renal	 cancer:	 it	 interacts	with	Ras	phosphoinositide-3-	kinase	(PI-3K)/PTEN/AKT	apoptosis	pathways	so	it	may	be	considered	a	clinical	biomarker	in	RCC.	In	a	recent	publication	[23]	some	of	us	recently	found	interesting	results	on	overexpression	of	miR21	 and	 miR210	 on	 urinary	 samples,	 and	 they	 also	 prove	 the	 significant	 reduction	 in	concentration	 of	 them	 after	 surgery	 and	 during	 follow-up.	 This	 finding	 seems	 to	 be	 very	interesting,	opening	new	doors	 for	genetic-	biomarkers	 in	ready	and	“easy	 to	collect”	 tissue	samples.		In	a	radiogenomics	approach	we	decided	to	compare	CT	texture	parameters	and	genetic	profile	of	ccRCC,	focusing	on	the	expression	of	miRNAs,	looking	for	correlation	between	them.	First	we	confirmed	deregulation	of	specific	miRNAs	in	our	group	of	20	ccRCC	(miR-21-5p,	miR-210-3p,	miR-185-5p,	miR-145-5p	and	miR-221-3p),	according	to	what	found	previously	[24].	In	 particular	 miR-21-5p	 and	 miR-210-3p	 are	 involved	 in	 ccRCC	 tumorigenesis	 and	 can	 be	considered	as	biomarkers	for	clear	cell	carcinoma.	In	parallel	most	of	CTTA	parameters	showed	significant	differences	comparing	normal	cortico-medullar	 tissue	with	 ccRCC.	CTTA	has	 robust	parameters	 to	distinguish	normal	 tissue	 from	clear	 cell	 carcinoma	 (e.g.	 entropy,	mean,	 sd).	This	 could	be	of	 great	 future	help	 for	 imaging	characterization	of	renal	lesion,	even	in	terms	of	survival	rates	and	clinical	outcome.	
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The	 surprising	 result	 of	 not	 significant	 increase	 of	 skewness	 and	 kurtosis	 in	 our	 cohort	 of	ccRCC,	 in	 contrast	 with	 previous	 studies	 on	 other	 solid	 tumours	 (e.g.	 rectal	 or	 lung	adenocarcinoma),	support	the	fact	that	different	tumours	display	different	radio-phenotypes	and	address	the	attention	to	more	research	in	this	field,	with	the	aim	of	looking	for	a	“texture	signature”	typical	for	every	tumour	type.	A	previous	study	from	Lubner	MG	et	Al	[25],	showed	a	difference	between	normal	liver	tissue	and	different	grades	of	liver	fibrosis,	in	particular	finding	increase	of	mean	grey	level	intensity	and	entropy,	while	decrease	of	skewness	and	kurtosis,	in	parallel	with	increasing	fibrosis	stage.	Regarding	the	comparison	between	expression	of	miRNA	and	modification	of	CTTA	in	tumour	samples,	 a	 surprisingly	poor	positive	 association	was	 found	among	 the	majority	 of	 them	 in	ccRCC	with	poor	statistical	significance.	Interesting	results	were	found	comparing	entropy	and	miR-21-5p	expression:	no	relation	was	found	with	normal	tissue,	while	tumour	entropy	is	slightly	positively	correlated.	The	results	are	almost	stable	moving	into	different	contrast-phases	and	different	spatial	filters,	giving	to	the	correlation	more	importance.	The	 correlation	was	 a	bit	 limited	by	data	 from	4	patients	 (20%),	who	had	a	 significant	up-regulation	 of	miR-21-5p	 but	 a	 slight	 increase	 of	 entropy	 in	 lesions	 as	 compared	 to	 normal	tissues.	The	reason	why	these	patients	showed	such	results	in	still	not	clear.	We	couldn’t	find	a	reasonable	factor	to	explain	this	behaviour,	since	patients	performed	the	same	CT	protocol	and	their	tissue	samples	were	either	fresh	frozen	(for	2)	or	FFPE	(for	the	others).	Furthermore,	they	were	 not	 different	 neither	 in	 terms	 of	 TNM	or	 grading,	without	 any	 apparent	 difference	 in	comparison	with	the	others.	The	only	interesting	common	factor	was	that	they	were	among	the	youngest	in	the	cohort	of	patients	(<60	years	of	age),	and	this	could	have	a	role	in	the	significant	hyper-expression	 of	 miRNA	 in	 tumour	 samples.	 More	 data	 are	 needed	 to	 support	 this	conclusion.	
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Nevertheless,	 without	 those	 4	 patients	 we	 found	 more	 significant	 results	 with	 very	 good	correlation.	Texture	 analysis	 is	 efficient,	 reproducible	 and	 it	 can	 be	 considered	 complementary	 to	 2D	imaging	evaluation	of	ccRCC	on	MDCT,	because	it	maximizes	the	information	obtained	from	the	lesion	and	it	has	the	potential	to	become	a	tool	for	prediction	of	prognosis.	Further	 studies	 with	 a	 larger	 cohort	 of	 patients	 and	 focusing	 on	 prognostic	 value	 of	 both,	miRNA	and	CTTA,	are	needed.	There	 are	 some	 limitations	 to	 the	 present	 study,	 the	 first	 is	 the	 small	 group	 of	 patients.	Moreover,	we	didn’t	perform	analysis	on	prognostic	value	of	the	parameters	because	of	lacking	of	outcome	data:	this	could	be	the	focus	for	our	next	research.	The	measurements	were	performed	on	pre-treatment	quite	large	renal	masses	and	in	2D	ROIs	on	three	different	levels	of	the	lesions	to	minimize	the	heterogeneity	in	MDCT	scans.	This	choice	has	 been	 made	 to	 avoid	 complicated	 volumetric	 measurements,	 supported	 by	 literature	suggesting	that	even	a	single	slice	measurement	may	be	enough.[26,	27].		 	
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Conclusion	In	conclusion	miRNA	and	CTTA	show	interesting	correlations	in	ccRCC	and	no	correlations	with	normal	tissues.	In	particular	there	is	a	correlation	between	entropy	and	miRNA	21-5p,	one	of	the	most	important	miRNA	involved	in	tumorigenesis;	in	addiction	our	results	reveal	that	CT	texture	 features,	 in	 particular	 mean	 and	 entropy,	 are	 correlated	 with	 ccRCC.	 This	 type	 of	information	 can	 be	 considered	 a	 useful	 non-invasive	 adjunct	 to	 biopsy	 results	 in	prognostication	and	patient	management.	 	 	
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Fig.	1	
	
Fig.	1	Flowchart	of	patients				 	
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Tab.	1	
Patient	demographics	and	characteristics	at	diagnosis	Number	of	patients	 20	Age	(years)	 65±3	Gender	 Male	 14	Female	 6	Body	Mass	Index	 		 27	kg/m2	±	4,37	Serum	Creatinine	 		 1,45	±	0,72	(mg/dl)	Smoking	habit	 yes	 13	no	 7	Patological	Tumour	stage	(pT)	pT1a	 11	pT1b	 4	pT2a	 1	pT2b	 1	pT3	 3	Surgical	procedure	 Tumorectomy	 7	Radical	nefrectomy	 13	Clear	cell	tumour	grade	 		 		1	 3	2	 15	3	 2	Tomour	Maximum	Diameter	 		 				 4,2±	2,4	cm	Abbreviations:	MSKCC=	Memorial	Sloan-Kettering	Cancer	Centre;	OS=overall	survival;	PFS=progression-free	survival		
Tab.	1	Patient	clinical	and	histological	characteristics	 	
“Sapienza” – Università di Roma 
	 62	 	
	
Table	2		
MDCT	parameters	 	Detector	Configuration	[mm]	 64	x	0.625	Tube	Voltage	[kV]	 120	Automatic	exposure	control	(AEC)	 On	Current	tube	modulation	[mAs]	 200/600	Noise	index	 28	Field	of	View	[cm]	 50	Rotation	Time	[sec.]	 0.5	Pitch	 1.375	Reconstruction	Kernel	 Medium-Smooth	Reconstruction	Algorithm	 Q30	Iterative	reconstruction	algorithm		 40%	Slice	thickness	[mm]	 1.25	
	
Table	2.	CT	acquisition	and	reconstruction	parameters.	
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Table	3	
	
	
	
Arterial	
Phase	
SSF	1.5	
Normal	tissue	
	
Tumour	
	
p-	value	 p-value	
Venous	
Phase	
p	value	
Urographic	
phase	mean	 -1.23	(±14.7)	 23.31	(±	17.38)	 <0.001	 <0.05	 <0.05	
sd	 101,2	(±37.8)	 120.9	(±32.7)	 <0.05	 0.09	 0.06	
entropy	 4.71	(±0.20)	 5.76	(±0.40)	 <0.001	 <0.05	 <0.05	
mpp	 85.39	(±38.75)	 107.17	(±33.1)	 <0.05	 <0.05	 <0.05	
skewness	 0.25	(±0.42)	 0.36	(±0.49)	 0.45	 0.52	 0.30	
kurtosis	 -0,04	(±0.63)	 1.67	(±5.50	 0.17	 0.23	 0.10	
	
Table	3.	expression	of	CTTA	 texture	parameters	 in	normal	 tissue	and	 tumour	 in	 arterial	 phase.	p	–	values	are	shown	for	arterious,	venous	and	urographyc	phase.	
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Figure	2	
A) B) 	
C)			 	
D) E) 		F)	 	
	
Figure	2.-	58	years	old	man	with	a	large	ccRCC	on	left	side.	A)-	B).	Portal	 venous	phase	 contrast	 enhanced	 transverse	 (A)	 and	 coronal	 (B)	CT	 images	 show	tumour	(arrows).	C).	Texture	analysis	image	show	ROI	(blue	line)	outlining	cancer.	D)-F).	Colour	texture	overlays	of	cancer	outlined	by	a	ROI	(blue	line)	show	images	with	a	fine	filtering	(spatial	scaling	factor,	1)	(D),	medium	filtering	(spatial	scaling	factor,	1.5)	(E),	and	coarse	filtering	(spatial	scaling	factor,	2)	(F).		 	
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Figure	3	
		
	 Mean	values	microRNAs	levels	(±	SD)	
	 miR-21-5p	 miR-210-5p	 miR-221-3p	 miR-185-5p	 miR-145-5p	
Normal	
tissue	
0.60	(±	0.51)	 1.18	(±	0.94)	 0.71	(±	0.32)	 1.08	(±	0.96)	 1.04	(±	0.33)	
ccRCC	 0.94	(±	0.61)	 1.57	(±	1.31)	 1.13	(±	0.74)	 1.03	(±	0.47)	 1.14	(±	0.65)	
p	value	 <	0.05	 <	0.05	 <	0.05	 >	0.05	 >	0.05		
Figure	3.		Evaluation	of	microRNAs	levels	in	clear	cell	renal	cell	carcinoma	(ccRCC)	patients		 	
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Tab.	4		
normal	tissue	 mean	 SD	 entropy	 mpp	 skewness	 kurtosis	
∆	(%)	miR-21	 0.30	 -0.14	 0.06	 -0.10	 -0.21	 0.09	
∆	(%)	miR	210	 -0.09	 -0.26	 0.23	 -0.27	 -0.28	 -0.21	
tumour	 mean	 SD	 entropy	 mpp	 skewness	 kurtosis	
∆	(%)	miR-21	 -0.24	 0.07	 0.24	 0.007	 0.04	 0.09	
∆	(%)	miR	210	 0.11	 0.15	 0.09	 0.17	 -0.01	 -0.13		
Tab.	4	CTTA	parameters	and	miRNA	Pearson	correlation	coefficient	r.	Statistically	significant	results	are	signed	with	*	 		 	
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Figure	4	
A) 		
B) 	
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C) 		
Fig.	4.	graphics	of	relation	and	R2	value	between	microRNAs	and	CTTA	features	in	ccRCC.	A)	On	the	x-axis	are	shown	%∆	of	mir-21-3p,	on	the	y	axis	are	shown	separately,	normal	tissue	entropy	and	tumour	tissue	entropy	(SSF1).	B)	x	axis:	%∆	miR	210-3p;	y	axis	normal	tissue	entropy	and	tumour	tissue	entropy	(SSF1)	C)	x	axis:	%∆	miR	21-3p;	y	axis	normal	tissue	skewness	and	tumour	tissue	skewness	(SSF1.5)		 	
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Fig.	 5	 Graphic	 of	 comparison	 between	 miR-21	 (expressed	 as	 %∆	 normal	 vs	 tumour)	 and	 entropy	excluding	4	patients	with	extremely	over-expression	of	miR-21	in	tumour	samples	(too	far	from	median	values).	As	shown	normal	tissue	entropy	have	a	worst	relation	than	tumour	tissue	with	miR21-3p.	This	latter	relation	is	very	good	with	a	R2	of	0.64			 	
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